IP Library Granted Patent US 10,766,876
Granted Patent B2
US 10,766,876 · App. 15/388,063 · Granted Sep 8, 2020

Cocrystal, production method thereof, and medicament containing cocrystal

Inventors: Koya Kimoto (Kanagawa, JP); Mitsuo Yamamoto (Kanagawa, JP); Masato Kitayama (Osaka, JP); Yasuhiro Sawai (Osaka, JP); Miyuki Hohokabe (Osaka, JP); Kentaro Iwata (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D401/14A61K31/4725C07C55/08C07C57/145C07C59/245C07C59/265C07C59/50C07C59/54C07C65/05C07C65/10C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,766,876
App. No.
15/388,063
Granted
Sep 8, 2020
Kind
B2
Abstract

The present invention provides a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and an organic acid capable of forming a cocrystal with the compound.

Claims (13)

1. A cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and gentisic acid, wherein the cocrystal shows a powder X-ray diffraction pattern having characteristic peaks at lattice spacings (d) of 13.04±0.2, 5.96±0.2, 4.67±0.2, 3.63±0.2 and 3.28±0.2 angstroms.

2. The cocrystal according to claim 1 , wherein a molar ratio of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and gentisic acid ((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one:gentisic acid) is 1:1.

3. A method of producing the cocrystal according to claim 1 , comprising mixing and stirring a strongly basic aqueous solution of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one, and a solution of gentisic acid.

4. The production method according to claim 3 , wherein the gentisic acid in the mixed solution of the strongly basic aqueous solution of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and the solution of the gentisic acid has a concentration of 0.298-0.592 mol/L.

5. The production method according to claim 3 , wherein the gentisic acid in the mixed solution of the strongly basic aqueous solution of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and the solution of the gentisic acid has a concentration of 0.388-0.592 mol/L.

6. The production method according to claim 3 , wherein a solvent of the solution of the gentisic acid is

(i) water,

(ii) at least one organic solvent selected from the group consisting of isopropyl alcohol, dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, 1-propanol, tetrahydrofuran, acetone, 2,2,2-trifluoroethanol, acetonitrile, 1-methyl-2-pyrrolidone, and acetic acid, or

(iii) a mixed solvent of at least one organic solvent selected from the group described in (ii) and water.

7. The production method according to claim 3 , comprising adding, as a seed crystal, a cocrystal of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one and gentisic acid to the mixture of the strongly basic aqueous solution of (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5 (4H)-one and the solution of the gentisic acid.

8. The cocrystal according to claim 1 , wherein the cocrystal shows a powder X-ray diffraction pattern having characteristic peaks at lattice spacings (d) of 13.04±0.2, 10.92±0.2, 9.97±0.2, 5.96±0.2, 4.67±0.2, 3.63±0.2 and 3.28±0.2 angstroms.

9. The cocrystal according to claim 1 , wherein the cocrystal shows a powder X-ray diffraction pattern having characteristic peaks at lattice spacings (d) of 13.04±0.2, 10.92±0.2, 9.97±0.2, 6.14±0.2, 5.96±0.2, 5.28±0.2, 4.67±0.2, 3.63±0.2 and 3.28±0.2 angstroms.

10. The cocrystal according to claim 1 , wherein the cocrystal is a nonhydrate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: KIMOTO, KOYA; YAMAMOTO, MITSUO; KITAYAMA, MASATO; SAWAI, YASUHIRO; HOHOKABE, MIYUKI; IWATA, KENTARO
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 041769/0712 →
Priority Claims (1)
JP 2015-252658 · Dec 24, 2015 · national
Continuity (1)
Related Publication 20170183326A1 · Jun 29, 2017